Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Conditions

• Diabetes Mellitus Type 2 Without Complication

Eligibility Criteria

Sex

ALL

Age

40 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• Dapagliflozin 10Mg Tab — DRUG
  Daily morning dose per oral of Dapagliflozin 10 mg for 7 days
• Empagliflozin 25 MG — DRUG
  Daily morning dose per oral of Empagliflozine 25 mg for 7 days
• Placebo — OTHER
  Daily morning dose per oral of Calcined magnesite 500 mg for 7 days

Study Details

To date one of the main independent biomarkers of cardiovascular disease is the arterial stiffness parameters measured by carotid-femoral pulse wave velocity. It is known that SGLT2 inhibitors develop cardiac protection over long term administration, but there's not enough studies about acute effects in early administration.

Key Dates

Start date

Mar 30, 2020

Status verified

Nov 2021

Primary completion

Jun 1, 2022

Completion

Aug 1, 2022

Study Design

Enrollment

72 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Arms

• Experimental: Dapagliflozin 10 mg
  Dapagliflozin is an oral medication used to treat Type 2 diabetes. It belongs to a sodium-glucose cotransporter 2 (SGLT2) inhibitors.
• Experimental: Empagliflozin 25 mg
  Empagliflozin is an oral medication used to treat Type 2 diabetes. It belongs to sodium-glucose cotransporter 2 (SGLT2) inhibitors.
• Placebo Comparator: Placebo
  Calcinated magnesium is a white powdery compound, MgO, used in pharmaceuticals as binder.

Primary Outcome Measure

Pulse wave velocity [ Time Frame: 7 days ]